A Randomized, Parallel-group, Double-blind Placebo-controlled and Open Label Active Controlled, Multi-center Study to Assess the Efficacy and Safety of Vilaprisan in Patients With Uterine Fibroids
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2017
At a glance
- Drugs Vilaprisan (Primary) ; Ulipristal
- Indications Uterine leiomyoma
- Focus Therapeutic Use
- Acronyms ASTEROID 2
- Sponsors Bayer HealthCare
- 03 Jul 2017 According to a Bayer media release, first results from this trial will be presented at an upcoming scientific congress.
- 21 Nov 2016 Status changed from active, no longer recruiting to completed.
- 24 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Oct 2016.